These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 23569309)
21. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial. Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G; Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091 [TBL] [Abstract][Full Text] [Related]
22. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA; Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220 [TBL] [Abstract][Full Text] [Related]
23. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Lück HJ; Du Bois A; Loibl S; Schrader I; Huober J; Heilmann V; Beckmann M; Stähler A; Jackisch C; Hubalek M; Richter B; Stickeler E; Eidtmann H; Thomssen C; Untch M; Wollschläger K; Schuster T; von Minckwitz G Breast Cancer Res Treat; 2013 Jun; 139(3):779-87. PubMed ID: 23771714 [TBL] [Abstract][Full Text] [Related]
24. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V; Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442 [TBL] [Abstract][Full Text] [Related]
25. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Murad AM; Guimarães RC; Aragão BC; Scalabrini-Neto AO; Rodrigues VH; Garcia R Am J Clin Oncol; 2001 Jun; 24(3):264-8. PubMed ID: 11404498 [TBL] [Abstract][Full Text] [Related]
26. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group. Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691 [TBL] [Abstract][Full Text] [Related]
27. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study. El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530 [TBL] [Abstract][Full Text] [Related]
28. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer. Delfino C; Caccia G; Gonzáles LR; Mickiewicz E; Rodger J; Balbiani L; Morales DF; Comba AZ; Brosio C Oncology; 2004; 66(1):18-23. PubMed ID: 15031594 [TBL] [Abstract][Full Text] [Related]
29. A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment. Xu B; Shen Z; Jiang Z; Guan Z; Zhang X Asia Pac J Clin Oncol; 2010 Dec; 6(4):320-9. PubMed ID: 21114782 [TBL] [Abstract][Full Text] [Related]
30. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Sledge GW Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403 [TBL] [Abstract][Full Text] [Related]
31. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. Bellmunt J; von der Maase H; Mead GM; Skoneczna I; De Santis M; Daugaard G; Boehle A; Chevreau C; Paz-Ares L; Laufman LR; Winquist E; Raghavan D; Marreaud S; Collette S; Sylvester R; de Wit R J Clin Oncol; 2012 Apr; 30(10):1107-13. PubMed ID: 22370319 [TBL] [Abstract][Full Text] [Related]
33. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145 [TBL] [Abstract][Full Text] [Related]
34. Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. Del Mastro L; Fabi A; Mansutti M; De Laurentiis M; Durando A; Merlo DF; Bruzzi P; La Torre I; Ceccarelli M; Kazeem G; Marchi P; Boy D; Venturini M; De Placido S; Cognetti F BMC Cancer; 2013 Mar; 13():164. PubMed ID: 23537313 [TBL] [Abstract][Full Text] [Related]
35. Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial. Lee KS; Ro J; Lee ES; Kang HS; Kim SW; Nam BH; Kwon Y; Kim EA; Shin KH Invest New Drugs; 2010 Feb; 28(1):83-90. PubMed ID: 19229476 [TBL] [Abstract][Full Text] [Related]
36. Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. Swain SM; Tang G; Geyer CE; Rastogi P; Atkins JN; Donnellan PP; Fehrenbacher L; Azar CA; Robidoux A; Polikoff JA; Brufsky AM; Biggs DD; Levine EA; Zapas JL; Provencher L; Northfelt DW; Paik S; Costantino JP; Mamounas EP; Wolmark N J Clin Oncol; 2013 Sep; 31(26):3197-204. PubMed ID: 23940225 [TBL] [Abstract][Full Text] [Related]
37. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. Nabholtz JM; Falkson C; Campos D; Szanto J; Martin M; Chan S; Pienkowski T; Zaluski J; Pinter T; Krzakowski M; Vorobiof D; Leonard R; Kennedy I; Azli N; Murawsky M; Riva A; Pouillart P; J Clin Oncol; 2003 Mar; 21(6):968-75. PubMed ID: 12637459 [TBL] [Abstract][Full Text] [Related]
38. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316 [TBL] [Abstract][Full Text] [Related]
39. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614 [TBL] [Abstract][Full Text] [Related]
40. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Fountzilas G; Christodoulou C; Tsavdaridis D; Kalogera-Fountzila A; Aravantinos G; Razis E; Kalofonos HP; Papakostas P; Karina M; Gogas H; Skarlos D Cancer Invest; 2004; 22(5):655-62. PubMed ID: 15581045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]